Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
Abstract This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6%; age, 60.5 years; DAS28-ESR, 4.3; treated with e...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-04075-0 |
| _version_ | 1798033423965618176 |
|---|---|
| author | Kosuke Ebina Toru Hirano Yuichi Maeda Wataru Yamamoto Motomu Hashimoto Koichi Murata Akira Onishi Sadao Jinno Ryota Hara Yonsu Son Hideki Amuro Tohru Takeuchi Ayaka Yoshikawa Masaki Katayama Keiichi Yamamoto Yasutaka Okita Makoto Hirao Yuki Etani Atsushi Kumanogoh Seiji Okada Ken Nakata |
| author_facet | Kosuke Ebina Toru Hirano Yuichi Maeda Wataru Yamamoto Motomu Hashimoto Koichi Murata Akira Onishi Sadao Jinno Ryota Hara Yonsu Son Hideki Amuro Tohru Takeuchi Ayaka Yoshikawa Masaki Katayama Keiichi Yamamoto Yasutaka Okita Makoto Hirao Yuki Etani Atsushi Kumanogoh Seiji Okada Ken Nakata |
| author_sort | Kosuke Ebina |
| collection | DOAJ |
| description | Abstract This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6%; age, 60.5 years; DAS28-ESR, 4.3; treated with either BAR (n = 166) or TOF (n = 185); bDMARDs- or JAKi-switched cases (76.6%). The reasons for drug discontinuation were classified into four major categories. The drug retention was evaluated at 24 months using the Kaplan–Meier method and multivariate Cox proportional hazards modelling adjusted by confounders. Discontinuation rates for the corresponding reasons were as follows; ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%) and remission (0.0%). Prior history of anti-interleukin-6 receptor antibody (aIL-6R) ineffectiveness significantly increased the risk of treatment discontinuation due to ineffectiveness (p = 0.020). Aging (≥ 75 years) (p = 0.028), usage of PSL ≥ 5 mg/day (p = 0.017) and female sex (p = 0.041) significantly increased the risk of treatment discontinuation due to toxic adverse events. Factors not associated with treatment discontinuation were: number of prior bDMARDs or JAKi, concomitant MTX usage, difference of JAKi, and prior use of TNF inhibitor, CTLA4-Ig or other JAKi. |
| first_indexed | 2024-04-11T20:30:15Z |
| format | Article |
| id | doaj.art-4f5b37cb670c499a922ca1bc68f13735 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T20:30:15Z |
| publishDate | 2022-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-4f5b37cb670c499a922ca1bc68f137352022-12-22T04:04:32ZengNature PortfolioScientific Reports2045-23222022-01-0112111010.1038/s41598-021-04075-0Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort studyKosuke Ebina0Toru Hirano1Yuichi Maeda2Wataru Yamamoto3Motomu Hashimoto4Koichi Murata5Akira Onishi6Sadao Jinno7Ryota Hara8Yonsu Son9Hideki Amuro10Tohru Takeuchi11Ayaka Yoshikawa12Masaki Katayama13Keiichi Yamamoto14Yasutaka Okita15Makoto Hirao16Yuki Etani17Atsushi Kumanogoh18Seiji Okada19Ken Nakata20Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of MedicineDepartment of Rheumatology, Nishinomiya Municipal HospitalDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of MedicineDepartment of Health Information Management, Kurashiki Sweet HospitalDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto UniversityDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto UniversityDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto UniversityDepartment of Rheumatology and Clinical Immunology, Kobe University Graduate School of MedicineDepartment of Orthopaedic Surgery, Nara Medical UniversityFirst Department of Internal Medicine, Kansai Medical UniversityFirst Department of Internal Medicine, Kansai Medical UniversityDepartment of Internal Medicine (IV), Osaka Medical and Pharmaceutical UniversityDepartment of Internal Medicine (IV), Osaka Medical and Pharmaceutical UniversityDepartment of Rheumatology, Osaka Red Cross HospitalInformation Technology Center, Wakayama Medical UniversityDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of MedicineDepartment of Orthopaedic Surgery, Osaka University Graduate School of MedicineDepartment of Orthopaedic Surgery, Osaka University Graduate School of MedicineDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of MedicineDepartment of Orthopaedic Surgery, Osaka University Graduate School of MedicineDepartment of Health and Sport Sciences, Osaka University Graduate School of MedicineAbstract This multi-center, retrospective study aimed to clarify the factors affecting drug retention of the Janus kinase inhibitors (JAKi) including baricitinib (BAR) and tofacitinib (TOF) in patients with RA. Patients were as follows; females, 80.6%; age, 60.5 years; DAS28-ESR, 4.3; treated with either BAR (n = 166) or TOF (n = 185); bDMARDs- or JAKi-switched cases (76.6%). The reasons for drug discontinuation were classified into four major categories. The drug retention was evaluated at 24 months using the Kaplan–Meier method and multivariate Cox proportional hazards modelling adjusted by confounders. Discontinuation rates for the corresponding reasons were as follows; ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%) and remission (0.0%). Prior history of anti-interleukin-6 receptor antibody (aIL-6R) ineffectiveness significantly increased the risk of treatment discontinuation due to ineffectiveness (p = 0.020). Aging (≥ 75 years) (p = 0.028), usage of PSL ≥ 5 mg/day (p = 0.017) and female sex (p = 0.041) significantly increased the risk of treatment discontinuation due to toxic adverse events. Factors not associated with treatment discontinuation were: number of prior bDMARDs or JAKi, concomitant MTX usage, difference of JAKi, and prior use of TNF inhibitor, CTLA4-Ig or other JAKi.https://doi.org/10.1038/s41598-021-04075-0 |
| spellingShingle | Kosuke Ebina Toru Hirano Yuichi Maeda Wataru Yamamoto Motomu Hashimoto Koichi Murata Akira Onishi Sadao Jinno Ryota Hara Yonsu Son Hideki Amuro Tohru Takeuchi Ayaka Yoshikawa Masaki Katayama Keiichi Yamamoto Yasutaka Okita Makoto Hirao Yuki Etani Atsushi Kumanogoh Seiji Okada Ken Nakata Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study Scientific Reports |
| title | Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study |
| title_full | Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study |
| title_fullStr | Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study |
| title_full_unstemmed | Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study |
| title_short | Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study |
| title_sort | factors affecting drug retention of janus kinase inhibitors in patients with rheumatoid arthritis the answer cohort study |
| url | https://doi.org/10.1038/s41598-021-04075-0 |
| work_keys_str_mv | AT kosukeebina factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT toruhirano factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT yuichimaeda factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT wataruyamamoto factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT motomuhashimoto factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT koichimurata factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT akiraonishi factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT sadaojinno factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT ryotahara factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT yonsuson factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT hidekiamuro factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT tohrutakeuchi factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT ayakayoshikawa factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT masakikatayama factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT keiichiyamamoto factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT yasutakaokita factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT makotohirao factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT yukietani factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT atsushikumanogoh factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT seijiokada factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy AT kennakata factorsaffectingdrugretentionofjanuskinaseinhibitorsinpatientswithrheumatoidarthritistheanswercohortstudy |